3.2. Secondary efficacy assessment
edema, redness, erosion, hemorrhage
EDEMA, EROSION, HEMORRHAGE
Based on the FAS analysis, the results (ORs) of the Wald test showed that patients in the CKD-495 75 mg group were more likely to have improvement than those in the AAF 60 mg group for erosion cure rate (OR, 1.76; 95% CI, 0.98–3.17), and improvement rates of edema (OR, 2.54; 95% CI, 0.37–17.38), redness (OR, 1.40; 95% CI, 0.50–3.86), and hemorrhage (OR, 1.72; 95% CI, 0.57–5.17) and self-reported GI symptoms (OR, 1.05; 95% CI, 0.58–1.90) (Fig. Primary and Secondary Efficacy endpoints results (ORs of the Wald test) (Full Analysis Set). OR = odds ratio.